{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:59:20Z","timestamp":1788184760697,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jbspin.2023.105591","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:16:16Z","timestamp":1684862176000},"page":"105591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4549-1723","authenticated-orcid":false,"given":"Thomas","family":"Machet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Qu\u00e9meneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ledoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6859-4851","authenticated-orcid":false,"given":"Rafik","family":"Mesbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-4051","authenticated-orcid":false,"given":"Celine","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2227-8017","authenticated-orcid":false,"given":"Mohammad Ryadh","family":"Pokeerbux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105591_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105591_bib0210","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0215","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0220","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2023.105591_bib0225","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105591_bib0230","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/rheumatology\/ker150","article-title":"Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"51","author":"Guerry","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105591_bib0235","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0240","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105591_bib0245","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody\u2013associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0250","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000509893","article-title":"Severe infections following rituximab treatment in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Li","year":"2021","journal-title":"Kidney Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0260","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0265","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105591_bib0270","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs. high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2023.105591_bib0275","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105591_bib0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/key117","article-title":"Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105591_bib0285","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated Vasculitis: clinical outcomes of remission induction therapy in AAV","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105591_bib0290","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0295","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key288","article-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody\u2013associated vasculitis","author":"Pepper","year":"2018","journal-title":"Rheumatology [Internet]"},{"key":"10.1016\/j.jbspin.2023.105591_bib0300","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.jbspin.2023.105591_bib0305","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2023.105591_bib0310","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3899\/jrheum.170896","article-title":"High Incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"46","author":"Kang","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0315","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/art.39762","article-title":"Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (Wegener's): a population-based study: cardiovascular disease in GPA","volume":"68","author":"Avi\u00f1a-Zubieta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0320","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: a retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0325","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim\u2013sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0330","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/annrheumdis-2020-218310","article-title":"Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients","volume":"80","author":"FAI2R\/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE consortium and contributors","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0335","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2023.105591_bib0340","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/03009742.2021.2001929","article-title":"Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy","volume":"52","author":"G\u00e9rard","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0345","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody\u2013associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2023.105591_bib0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2023.105591_bib0355","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study","volume":"34","author":"Martinez Del Pero","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0365","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13023-020-01621-3","article-title":"French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)","volume":"15","author":"Terrier","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0370","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0375","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","article-title":"Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: the RAVE Trial Revisited","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2023.105591_bib0380","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2023.105591_bib0385","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/BOR.0000000000000508","article-title":"Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"30","author":"Cohen Tervaert","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105591_bib0390","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1093\/rheumatology\/keab267","article-title":"The role of trimethoprim\/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis","volume":"60","author":"Monti","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2023.105591_bib0395","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105591_bib0400","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:31:47Z","timestamp":1761150707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1297319X23000702"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105591","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105591"}}